Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBurping on semaglutide is common, particularly in the first few weeks of treatment or after a dose increase. It happens because semaglutide slows the rate at which your stomach empties (a deliberate part of how the medicine works) and that slower transit tends to push trapped air upward. For most people, the semaglutide burping settles as the body adjusts, though some strategies can make it more manageable in the meantime. These medicines are prescription-only and require clinical assessment before they're prescribed; a qualified prescriber decides whether they're appropriate for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people who contact their prescriber about burping on semaglutide are trying to answer one question: is this normal, and is it going to pass? That's the right question. Burping sits in the same family as nausea, reflux and mild indigestion — the classic gastrointestinal effects of GLP-1 medicines documented across clinical trials and in the NHS patient guide for semaglutide. The mechanism is straightforward: semaglutide activates GLP-1 receptors in the gut, which slows gastric emptying. Food and gas sit in the stomach longer than usual, and when that gas moves, it moves upward.
The decision most people face isn't really a binary choice between tolerating it or quitting. There's a middle path: small adjustments to eating and drinking habits that reduce the volume of air entering the stomach in the first place. Understanding which category your symptoms fall into shapes what you do next. Mild, intermittent belching? Likely adjustable. Frequent, disruptive burping that affects mealtimes and sleep? Worth discussing with your prescriber before your next scheduled review. Something else (severe pain, vomiting, fever) means ringing 111 or your GP today, not waiting.
For a fuller picture of Wegovy's side effect profile, including which symptoms are common versus those that need prompt attention, that page covers the full range.
Gastric emptying on semaglutide is slower by design. That's part of why appetite drops and meals feel more satisfying sooner. The trade-off is that gas produced during digestion, or swallowed with food and drink, has more time to accumulate before the stomach moves it along. The result is eructation (the medical term for burping) that can feel more frequent or more forceful than usual.
Several factors make it worse for some people more than others. Carbonated drinks are an obvious one: fizzy water, sparkling mixers and soft drinks add a direct bolus of gas to an already slower-emptying stomach. Eating quickly (swallowing more air with each mouthful) compounds this. Large meals that were manageable before treatment can feel overwhelming on semaglutide because the stomach's capacity to process them quickly has changed. There's also an element of individual variation: some people barely notice this side effect, others find it the most bothersome aspect of the early weeks.
The pattern described by people on semaglutide (documented across STEP trial participants and reflected in post-marketing reports) tends to follow dose changes. If you noticed the burping most after starting or moving to a higher strength, that's consistent with how the medicine behaves. The question of whether semaglutide directly causes burping versus worsening existing reflux tendencies is answered in detail on that page, but the short version is: both are possible, and the distinction matters for management.
None of these require a prescription change. They're adjustments to eating and drinking patterns that reduce how much gas reaches the stomach in the first place, and slow down how quickly it builds up.
Eat slowly. This sounds obvious, but the pace most people ate before starting semaglutide doesn't match the slower gastric emptying they now have. Putting the fork down between bites, chewing thoroughly, and stopping when comfortably full rather than at a plate-clearing endpoint all reduce swallowed air and the volume the stomach is asked to process at once. Smaller, more frequent meals tend to produce fewer symptoms than two or three large ones, particularly in the first few weeks at a new dose.
Cut carbonated drinks, at least temporarily. This includes sparkling water, which people often switch to when trying to drink more. Still water, herbal teas and plain drinks remove one of the most direct sources of extra gas. Fatty or heavily spiced food slows gastric emptying further, so the NHS guidance on semaglutide recommends keeping fat intake moderate while the body adjusts. There's more on the specific phenomenon of egg-flavoured burping on semaglutide, a more distinctive symptom that sometimes prompts separate questions.
Posture after eating matters too. Staying upright for 30 to 60 minutes after a meal supports normal gastric function and makes it easier for the stomach to process gas appropriately. Lying down immediately after eating tends to worsen both burping and reflux on any GLP-1 medicine.
If you're finding that burping is also waking you up or hitting hardest at night, there's separate guidance on nocturnal gastrointestinal symptoms on Wegovy that applies some of the same principles to overnight patterns.
Most burping on semaglutide is self-limiting. The body adapts to the new gastric-emptying rate, eating habits adjust, and within a few weeks it becomes a background nuisance at worst. That said, two scenarios warrant contacting your prescriber rather than waiting.
First: burping that doesn't ease after two to four weeks at the same dose, or that returns persistently after every meal, might indicate that the current dose is harder to tolerate than expected. Your prescriber can weigh whether slowing the titration pace makes sense, that's a clinical call, not one to make unilaterally by skipping injections.
Second, and more urgently: burping accompanied by severe, persistent stomach pain (particularly pain that spreads to the back, doesn't ease with position changes, or comes with significant nausea and vomiting) is a different symptom cluster entirely. The MHRA's guidance on GLP-1 medicines identifies acute pancreatitis as a serious but infrequent risk; the MHRA Yellow Card scheme is where any suspected serious reaction should be reported, and the NHS advises seeking urgent medical help for any severe abdominal pain on these medicines, not managing it at home. That's the line between a side effect and a warning sign.
If you're not yet on treatment and are weighing up how side effects like this might affect you, the full Wegovy overview covers what to expect across the full course of treatment. And if questions are piling up before a consultation, our FAQs address many of the practical concerns people raise. The cost of private treatment, for those factoring that in, is covered on the Wegovy cost page.
When you're ready to talk to a prescriber about whether semaglutide is right for you, start your free consultation with the nume clinical team, your answers are reviewed the same day by a GPhC-registered prescriber, not automated software.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.